Evidence map›Paper›PMID 42191843›Full record

ArticleCommunications biology2026

Viral mimicry redirects immunosuppressed colorectal tumour landscapes towards a proinflammatory and CMS1-like regenerative state.

Shania M Corry, Svetlana Sakhnevych, Noha Ehssan Mohamed, Sudhir B Malla, Ryan Byrne, Andrew Young, Raheleh Amirkhah, Courtney Bull, Andrea Lees, Keara Redmond and 13 more

Abstract read
In one paragraph

Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Shania M Corry *The Johnston Cancer Research Centre, Queen's University Belfast, Belfast, UK. Shania.corry@well.ox.ac.uk.ORCID 0009-0007-3430-8125
Svetlana Sakhnevych *The Johnston Cancer Research Centre, Queen's University Belfast, Belfast, UK.
Noha Ehssan Mohamed *Cancer Research UK Scotland Institute, Glasgow, UK.
Sudhir B MallaThe Johnston Cancer Research Centre, Queen's University Belfast, Belfast, UK.ORCID 0000-0001-5862-3815
Ryan ByrneThe Johnston Cancer Research Centre, Queen's University Belfast, Belfast, UK.ORCID 0000-0001-6505-6345
Andrew YoungThe Johnston Cancer Research Centre, Queen's University Belfast, Belfast, UK.
Raheleh AmirkhahThe Johnston Cancer Research Centre, Queen's University Belfast, Belfast, UK.ORCID 0000-0003-3494-271X
Courtney BullThe Johnston Cancer Research Centre, Queen's University Belfast, Belfast, UK.
Andrea LeesThe Johnston Cancer Research Centre, Queen's University Belfast, Belfast, UK.
Keara RedmondThe Johnston Cancer Research Centre, Queen's University Belfast, Belfast, UK.
Tamsin R M LannaganCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0002-8206-8898
Rachel A RidgwayCancer Research UK Scotland Institute, Glasgow, UK.
Fiona R TaggartThe Johnston Cancer Research Centre, Queen's University Belfast, Belfast, UK.
Natalie C FisherThe Johnston Cancer Research Centre, Queen's University Belfast, Belfast, UK.
Tim MaughanUniversity of Liverpool, Liverpool, UK.
Mark LawlerThe Johnston Cancer Research Centre, Queen's University Belfast, Belfast, UK.
Andrew D CampbellCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0003-3930-1276
Simon J LeedhamWellcome Centre for Human Genetics, Oxford, UK.ORCID 0000-0003-1476-6982
Aideen E RyanDiscipline of Pharmacology & Therapeutics, School of Medicine, College of Medicine, Nursing and Health Sciences, University of Galway, Galway, Ireland.ORCID 0000-0002-5831-6783
Daniel B LongleyThe Johnston Cancer Research Centre, Queen's University Belfast, Belfast, UK.
Donna M SmallThe Johnston Cancer Research Centre, Queen's University Belfast, Belfast, UK.
Owen J SansomCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0001-9540-3010
Philip D DunneThe Johnston Cancer Research Centre, Queen's University Belfast, Belfast, UK. p.dunne@qub.ac.uk.ORCID 0000-0001-9160-283X

Funding

Cancer Research UK (CRUK) A26825Cancer Research UK (CRUK) A29834Cancer Research UK (CRUK) SEBCRCS-2024/100001RCUK | Medical Research Council (MRC) MC_PC_21042
6 · The paper itself

Abstract

In colorectal cancer (CRC), tumours classified as consensus molecular subtype 4 (CMS4) have the worst prognosis and derive negligible benefit from chemotherapy. We previously described how repressed interferon-related signalling is associated with increased relapse in CMS4 tumours. Although the viral mimetic polyinosinic:polycytidylic acid, poly(I:C), can reduce liver metastasis in vivo, the initial phenotypic changes that underpin its anti-metastatic response remain poorly described, particularly in the immunosuppressed CMS4 tumour microenvironment. Here we characterise lineage-specific anti-metastatic responses induced by poly(I:C), including acute macrophage polarisation and a novel CMS1-like regenerative stem cell state, which drive pro-inflammatory microenvironmental changes in CRC. These insights enabled the development of tractable biomarkers that identify an "immune-warm" patient subset most likely to respond to poly(I:C), enriched for mismatch-repair proficient (pMMR), anti-inflammatory macrophages and CMS4-like features. The viral mimetic poly(I:C) offers a tailored treatment option for poor-prognostic tumours, by reprogramming stem cell states and activation of an innate-adaptive anti-metastatic response.

Indexed as

Colorectal NeoplasmsPoly I-CTumor MicroenvironmentAnimalsHumansInflammationMacrophagesPoly I-C

Identifiers

PMID42191843
PMCPMC13486658

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.